McKesson Health Solutions, a company that specializes in helping patients with medical payments, recently announced its new analytics system HealthQx received certification in the Prometheus Analytics model. Read More »
Teva Pharmaceutical Industries' chairman Yitzhak Peterburg has been appointed interim president and chief executive officer. Read More »
Global pharmaceutical leader Allergan is launch a new campaign to bring awareness to blindness, and commit to fighting preventable blindness in the United States in its new See America initiative. Read More »
The U.S. Food and Drug Administration has approved deflazacort, a new treatment for Duchenne muscular dystrophy in patients 5 years and older. Read More »
The U.S. Food and Drug Association is reviewing AbbieVie's New Drug Application (NDA) for a new treatment of Hepatitis C virus. Read More »
The U.S. Federal Trade Commission has filed a civil action suit against a subsidiary of Shire, PLC, as part of a citizen petition submission regarding antibiotic Vancocin. Read More »
The recent 2017 Economic Report on Pharmacies and Pharmacy Benefit Managers by Drug Channels named the top 15 U.S. Pharmacies of 2016. Read More »
Allergan has made a substantial donation to the American Association for the Study of Liver Diseases Foundation, becoming part of AASLD’s Founder’s Society. Read More »
Acorda Therapeutics' CVT-301, a drug used in treating people with Parkinson’s disease, showed significant improvement in motor functions during a Phase 3 clinical trial. Read More »
The FDA issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain. Read More »
Precision for Value and the National Committee for Quality Assurance have partnered to integrate data collected in the Healthcare Effectiveness Data and Information Set into the quality measuring tool Qnav. Read More »
The Pharmaceutical Research and Manufacturers of America submitted comments this month to the 2017 Special 301 Report. Read More »
Portola Pharmaceuticals recently signed a $150 million royalty agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanat Alfa, an antidote for Factor Xa inhibitors. Read More »
SPX-101, a new compound designed by Spyryx Biosciences, recently passed a Phase 1 study for the treatment of severe lung disease, including cystic fibrosis. Read More »
Palatin Technologies Inc. has closed its license agreement with AMAG Pharmaceuticals Inc. for the development of Rekynda in North America. Read More »
Biogen Inc., a global pharmaceutical manufacture, has launched a subsidiary global hemophilia business, Bioverativ. Read More »
CVS Health Research Institute recently released a statement on its decision to stop selling tobacco products and the research behind that decision. Read More »
3M Drug Delivery Systems will continue its collaboration with Panacea Pharmaceuticals Inc., this time working on a new phase in its study of an investigational therapeutic cancer vaccine that would be delivered to the dermis via 3M's Hollow Microstructured Transdermal System. Read More »
The U.S. Food and Drug Administration has granted Perrigo Co. final approval for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup) 5 mg/1.5mg per 5 mL. Read More »
The U.S. Food and Drug Administration recently reclassified Class I devices, which are antigen-based rapid influenza antigen detection systems that are meant to detect the virus from clinical specimens, to Class II devices that are subject to special controls, according to PRNewswire. Read More »
Alerts Sign-up
